Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer.

Oncogene - 8 Mar 2007

Choi S H, Mendrola J M, Lemmon M A

Abstract excerpt

Several somatic mutations within the tyrosine kinase domain of epidermal growth factor receptor (EGFR) have been identified that predict clinical response of non-small-cell lung carcinoma (NSCLC) patients to gefitinib. To test the hypothesis that these mutations cause constitutive EGF receptor signaling, and to investigate its mechanistic basis, we expressed representative examples in a null background and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Membrane
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Models, Molecular

Share to Mutation

Share to Phosphorylation

Share to Protein Binding

Source

Identifiers

PMID: 16953218
DOI: 10.1038/sj.onc.1209957

Genes

EGF
EGFR
F3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer.PMID 16953218Read ↗

Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants.Semantic proximity Read ↗

Inhibition of mutant EGF receptors by gefitinib: targeting an Achilles' heel of lung cancer.Semantic proximity Read ↗

Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.Semantic proximity Read ↗

Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants.Semantic proximity Read ↗

EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy.Semantic proximity Read ↗

Ligand-Independent EGFR Signaling.Semantic proximity Read ↗

Activating ERBB4 mutations in non-small cell lung cancer.Semantic proximity Read ↗

Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy.Semantic proximity Read ↗

Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.Semantic proximity Read ↗

An unbiased in vitro screen for activating epidermal growth factor receptor mutationsSemantic proximity Read ↗

Epidermal growth factor receptor as a target enzyme in cancer therapy: Structural and functional insights from crystallography.Semantic proximity Read ↗

Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.